These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12084003)

  • 1. Rheumatoid arthritis: developing pharmacological therapies.
    Misischia RJ; Moreland LW
    Expert Opin Investig Drugs; 2002 Jul; 11(7):927-35. PubMed ID: 12084003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the treatment of rheumatoid arthritis: old versus new therapies.
    Saravanan V; Hamilton J
    Expert Opin Pharmacother; 2002 Jul; 3(7):845-56. PubMed ID: 12083985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs for the treatment of rheumatoid arthritis.
    Schuna AA; Megeff C
    Am J Health Syst Pharm; 2000 Feb; 57(3):225-34. PubMed ID: 10674776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [TNF targetting therapy for rheumatoid arthritis].
    Takeuchi T
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].
    Kondo H
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):153-60. PubMed ID: 14968591
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The yin and yang of tumor necrosis factor inhibitors.
    Calabrese L
    Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 13. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.
    Inanc N; Direskeneli H
    Rheumatol Int; 2006 Nov; 27(1):67-71. PubMed ID: 16896990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-TNF agents for rheumatoid arthritis.
    Seymour HE; Worsley A; Smith JM; Thomas SH
    Br J Clin Pharmacol; 2001 Mar; 51(3):201-8. PubMed ID: 11298065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].
    Pérez Pampín E; Gómez-Reino Carnota JJ
    Med Clin (Barc); 2008 Feb; 130(5):179-87. PubMed ID: 18341834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.
    Mikuls TR; Moreland LW
    Expert Opin Pharmacother; 2001 Jan; 2(1):75-84. PubMed ID: 11336570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.